KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Share-based Compensation (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Share-based Compensation data on record, last reported at $9.6 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 40.2% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $41.7 million, down 41.34%, while the annual FY2025 figure was $41.7 million, 41.34% down from the prior year.
  • Share-based Compensation reached $9.6 million in Q4 2025 per PACB's latest filing, down from $11.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $28.4 million in Q3 2021 and bottomed at $9.2 million in Q1 2025.
  • Average Share-based Compensation over 5 years is $17.2 million, with a median of $18.0 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 611.19% in 2021, then plummeted 52.88% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $18.9 million in 2021, then dropped by 5.19% to $18.0 million in 2022, then fell by 7.64% to $16.6 million in 2023, then dropped by 3.32% to $16.0 million in 2024, then crashed by 40.2% to $9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $9.6 million in Q4 2025, $11.0 million in Q3 2025, and $11.9 million in Q2 2025.